// App-Quantinova.ai

LBA48 : ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Researchers

Presenter

  • D.Morgensztern

Principal Investigators

  • T.J.Ong

  • M. CoboDols

  • S. PonceAix

  • P.E.Postmus

  • C.Lewanski

  • J.Bennouna

  • J.R.Fischer

  • O.J.Vidal

  • D.J.Stewart

  • G.Fasola

  • A.Ardizoni

  • J.Weaver

  • M.Wolfsteiner

  • D.Talbot

  • R.Govindan

Medical Centers

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Oncology, Celgene Corporation, Summit, USA

  • Medical Oncology, Hospital Regional Universitario Carlos Haya – Hospital General, Malaga, Spain

  • Oncology, Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO, Madrid, Spain

  • Medical Oncology, The Clatterbridge Cancer Centre, Liverpool, UK

  • Charing Cross Hospital, London, UK

  • Thoracic Oncology, Centre René Gauducheau Centre de Lutte Contre le Cancer Nantes Atlantique, Nantes, Loire-Atlantique, France

  • Medical Oncology, Lungenklinik Löwenstein, Löwenstein, Baden-Württemberg, Germany

  • Pediatric Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain

  • Medicine, Ottawa Hospital, ottawa, ON, Canada

  • University Hospital S. Maria della Misericordia, Udine, Italy

  • Oncology, Azienda Ospedaliero Universitaria Di Bologna - Policlinico S. Orsola Malpighi, Bologna, Italy

  • Oncology, PRA Health Sciences, Lenexa, KS, USA

  • Oncology, Oxford University Hospitals Trust, Oxford, UK

Locations

  • United States

  • Spain

  • United Kingdom

  • France

  • Germany

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

  • Paclitaxel

  • CC-486

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved